Introduction:We present two cases of T1D with binge eating disorder(BED) benefitted by GLP-1 agonists with Hybrid closed loop(HCL) insulin pump(CSII).

Case 1:35-year-old female with T1D, obesity had high diabetes distress score(DDS), fear of hypoglycaemia, and emotional eating. She was on non-HCL CSII (Tandem Diabetes Care t:slim X2™ Insulin Pump), later Dexcom G6® Continuous Glucose Monitoring(CGM) with Control-IQ™ Technology and insulin Lispro for binge eating hyperglycaemia. She was supported by motivational interviewing, commenced Dulaglutide injections. Her food cravings reduced, felt positive about diabetes self-management and insulin requirement reduced by 25%.

Case 2:42-year-old female with T1DM, obesity, poor compliance, multiple diabetic ketoacidosis (DKA), nephropathy, retinopathy, diabulimia, high DDS; was commenced on Dulaglutide injections with HCL CSII (MiniMed™ 780G system with SmartGuard™ technology and Guardian™ 4 CGM). Renal function, quality of life score improved; insulin requirement reduced by 32%

Discussion:GLP-1 agonists with HCL CSII improved patient satisfaction scores, metabolic profile, weight, HbA1c, insulin requirement, blood pressure with no increase in DKA or hypoglycaemia. GLP-1 agonists are beneficial in binge eating without diabetes. Larger studies for complex T1D, diabetes distress, diabulimia may be warranted.

graphic
View largeDownload slide
Disclosure

N. Basavaraju: None. A. Jones: None. P. Moulik: None.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.